Edotreotide

Known as: DOTA-Tyr3-octreotide, DOTATOC, (DOTA(0)-Phe(1)-Tyr(3))octreotide 
A chelated octreotide derivative with somatostatin activity. Edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Peptide receptor radionuclide therapy (PRRNT) is a molecularly targeted radiation therapy involving the systemic administration… (More)
  • table 1
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE Metastatic carcinoid is an incurable malignancy whose symptoms, such as diarrhea and flushing, can be debilitating and… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumours with 90Y-DOTATOC and 177Lu-DOTATATE is promising. The… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Neuroendocrine tumours (NETs) can be imaged with scintigraphy using radiolabelled somatostatin analogues. The aim of our study… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
UNLABELLED The (68)Ge/(68)Ga generator provides an excellent source of positron-emitting (68)Ga. However, newly available "ionic… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
UNLABELLED Nephrotoxicity is the major limiting factor during therapy with the radiolabeled somatostatin analog (90)Y-1,4,7,10… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
UNLABELLED The aim of this prospective phase II study was to evaluate the tumor response of neuroendocrine tumors to high-dose… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
The aim of this study was to determine the maximum tolerated dose of 90Y-DOTATOC per cycle administered in association with amino… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2001
Highly Cited
2001
PURPOSE The aim of this phase II study was to evaluate the tumour response of neuroendocrine tumours to targeted irradiation with… (More)
Is this relevant?
Highly Cited
1999
Highly Cited
1999
In a pilot study, DOTA-d-Phe1-Tyr3-octreotide (DOTATOC), which can be labelled with the β-emitting radioisotope yttrium-90, has… (More)
  • table 2
  • figure 2
  • figure 1
  • figure 4
  • figure 3
Is this relevant?